Plasma fibrinogen levels in sickle cell disease

Area of Science:

• Hematology
• Vascular Biology
• Genetic Blood Disorders

Background:

• Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal hemoglobin.
• Vascular complications, including occlusion, are a major cause of morbidity and mortality in SCD.
• Fibrinogen is a key protein in blood coagulation and clot formation.

Purpose of the Study:

• To compare plasma fibrinogen levels in patients with homozygous sickle cell disease (HbSS) versus non-sickle cell individuals.
• To investigate the potential role of elevated fibrinogen in the severity of SCD complications.

Main Methods:

• Plasma fibrinogen levels were quantified using a clotweight method.
• Measurements were taken from 25 patients with HbSS during steady state.
• A control group of 36 age-matched non-sickle cell individuals was included for comparison.

Main Results:

• Mean fibrinogen levels were significantly higher in HbSS patients (5.3 +/- 2.0 g/l) compared to non-sickle cell individuals (3.1 +/- 1.0 g/l) (p < 0.001).
• No significant sex-based differences in fibrinogen levels were observed within either group.
• The range of fibrinogen levels in HbSS patients was notably wider (3.0-11.5 g/l) than in controls (2.0-5.5 g/l).

Conclusions:

• Elevated plasma fibrinogen is a characteristic finding in individuals with homozygous sickle cell disease.
• Increased fibrinogen levels may represent an additional factor contributing to the severity of vascular occlusion events in SCD.
• Further research is warranted to explore therapeutic strategies targeting fibrinogen in SCD management.